What the question is testing
This item asks you to recognize the
most feared complication of IV alteplase for acute ischemic stroke:
symptomatic intracranial hemorrhage. The clinical picture is deliberately classic, and the timing during the infusion is the key clue.
Why intracranial hemorrhage is the answer
Alteplase is a
recombinant tissue plasminogen activator that converts plasminogen to plasmin, leading to
systemic fibrinolysis. In the brain, this lytic state can disrupt the blood–brain barrier and weaken already injured vessels in the ischemic penumbra, allowing blood to extravasate into brain tissue. The result is
hemorrhagic transformation, which becomes clinically apparent as
symptomatic intracranial hemorrhage when it causes neurologic deterioration.
The patient’s findings fit that process precisely. A
sudden severe headache, vomiting, acute hypertension, and a declining level of consciousness during alteplase infusion are the hallmark signs of sICH. The blood pressure of
198/112 mmHg is especially concerning because extreme hypertension during thrombolysis both reflects rising intracranial pressure and worsens ongoing bleeding. The change in arousal indicates that the hemorrhage is now producing a mass effect or direct brainstem compression.
Watch out! Do not call this an “expected” headache. A mild headache can occur during thrombolysis, but a
sudden, severe headache with vomiting and neurologic worsening is never expected and must be treated as sICH until proven otherwise.
Why the other options are less likely
| Option | Why it is not the best answer |
|---|
| 2. Expected headache as the clot is dissolved | Clot dissolution itself does not produce a sudden severe headache, vomiting, or a falling level of consciousness. These are neurologic emergency signs, not normal treatment effects. |
| 3. Malignant cerebral edema from a large infarct | Malignant edema typically develops over 24–72 hours after a large infarct, not within 40 minutes of starting alteplase. The abrupt onset during infusion points to hemorrhage rather than gradual edema. |
| 4. Extension of the original ischemic infarct | Ischemic extension can worsen deficits, but the combination of sudden severe headache, vomiting, and marked hypertension is far more specific for hemorrhagic conversion. In addition, alteplase is actively lysing clot, which makes hemorrhage more biologically plausible than new large-vessel occlusion at this moment. |
Pathophysiology of hemorrhagic transformation
Ischemic stroke damages the endothelium and basal lamina of cerebral vessels. When alteplase is given,
plasmin activation degrades fibrin and other extracellular matrix components, including
laminin and fibronectin in the vessel wall. This weakens the blood–brain barrier. Reperfusion into damaged capillaries then leads to leakage or frank rupture, producing
petechial hemorrhage or a larger
parenchymal hematoma. The more severe the ischemic injury and the longer the vessel has been occluded, the higher the risk of hemorrhagic conversion.
Key point! The risk of intracranial hemorrhage is higher with thrombolysis for acute ischemic stroke than with thrombolysis for myocardial infarction or pulmonary embolism. In stroke thrombolysis, reported intracranial hemorrhage rates range from about
6.4% to 20%, whereas thrombolysis for acute MI or PE carries a cerebral hemorrhage risk of less than
2%. This difference reflects the underlying cerebral vascular injury that is already present in stroke.
Immediate nursing and team actions
The priority is to
stop the alteplase infusion immediately and notify the provider. Emergency noncontrast CT is obtained to confirm hemorrhage and assess its size and location. Blood pressure must be controlled aggressively, because ongoing hypertension worsens hematoma expansion. Coagulation studies, including
fibrinogen, PT/INR, and aPTT, are drawn to guide reversal. If hemorrhage is confirmed,
cryoprecipitate or
antifibrinolytic agents such as tranexamic acid may be considered, although the evidence for specific reversal strategies remains limited and is based largely on expert opinion and small case series.
Why this matters for the licensure exam
This scenario tests your ability to recognize a
time-critical adverse event during thrombolytic therapy. The exam will expect you to know that any sudden neurologic worsening, severe headache, vomiting, or acute blood pressure elevation during alteplase infusion means
stop the infusion and obtain emergency imaging. Do not wait for the infusion to finish, and do not attribute these findings to anxiety, positioning, or normal clot lysis. The correct nursing response is always to suspect sICH first and act immediately.